top of page

Lixa receives ethics approval for Phase I trial of NeoX-101

27 June 2024

Lixa is delighted to announce that we have received Human Research Ethics Committee (HREC) approval to commence our first human trial - a Phase I clinical trial assessing the safety and tolerability of NeoX™ in an inhaled formulation. 

This is a major step closer to reaching patients suffering from chronic, resistant respiratory infections. By successfully proving the safety and tolerability of an inhaled formulation of NeoX-101, Lixa will look forward to progressing into patient trials.


A big shout out to our strategic projects leader, Kristen Houston, interim chief medical officer Prof Paul Rolan, and Quality manager Virginia Castro. Thanks also to our CSO, Andrew Barker and the R&D team for supporting activities.

bottom of page